Stock Financial Ratios, Dividends, Split History
PLX / Protalix BioTherapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||65.36|
|Enterprise Value ($M)||24.04|
|Book Value ($M)||-39.44|
|Book Value / Share||-0.27|
|Price / Book||-1.66|
|NCAV / Share||-0.33|
|Price / NCAV||-1.35|
|Percentage Of Excess Shares Outstanding||0|
|Common Stock Shares Outstanding||143,728,797|
|Common Shares Outstanding||145,569,955|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||2.73|
|Return on Assets (ROA)||-1.04|
|Return on Equity (ROE)||8.56|
|Income Statement (mra) ($M)|
|Sales Revenue Goods Net||0.00|
|Revenues Other Than Company Share In Collaboration Agreement||0.00|
|Disposal Group Including Discontinued Operation Revenue||0.00|
|Earnings Per Share Basic And Diluted||-0.65|
|Earnings Per Share Basic||-0.65|
|Earnings Per Share Diluted||-0.65|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-9.99|
|Cash from Investing||-1.12|
|Cash from Financing||-1.12|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1006281|
Stock splits are used by Protalix BioTherapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2017-10-02 - Asif
Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins. On May 1, 2012, the F...
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
5h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Morgan Stanley, Cowen, Wells Fargo and Wedbush Pacgrow will help the company sell 22,313,687 shares at $16-$18 per share. (181-9)
Protalix is innovating a novel approach to enzyme replacement therapy and other protein therapeutics based on the plant cells manufacturing system. (59-1)
Good day, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference Mr. Yossi Maimon, Chief Financial Officer, you may begin. (59-0)
Despite having risen nearly 50% from 2017 lows of $2, PDLI biopharma (PDLI) remains undervalued, and activist investors are starting to notice. Recent activist behavior from SevenSaoi Capital could act as yet another catalyst for PDL’s price to increase towards book value of $5.84, nearly 110% higher than the current price of $2.9. (200-3)
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team. (138-2)
as of ET